X4 Pharmaceuticals announced the acceptance of two abstracts for presentation at the upcoming European Hematology Association Congress regarding the positive results from their Phase 2 trial of ...

Close monitoring via weekly complete blood counts (CBCs) for the first 2 months is essential to mitigate risks, according to Zeidan. Supportive care such as platelet transfusions or growth factors may ...

Spectrum Pharmaceuticals develops and commercializes cancer therapies, including Rolvedon (formerly eflapegrastim), a long-acting G-CSF for treating chemotherapy-induced neutropenia (CIN). The FDA's ...

This study aimed to identify the patient characteristics of children with febrile neutropenia, the associated bacterial organisms, and their sensitivity patterns. A descriptive cross-sectional study ...

Neonatal alloimmune neutropenia is due to maternal production of antibodies directed against neutrophil specific antigens (NA1, NA2, NB1, NC1) reacting with fetal-neonatal and paternal neutrophils.

The PALLAS trial analyzed the impact of BMI in patients with early hormone receptor positive breast cancer. Body mass index (BMI) had an effect on side effects, dose reductions, early treatment ...

New York, July 21, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Neutropenia Treatment Market By Distribution channel, By ...

Research and Markets has announced the addition of the "Global Neutropenia Treatment Market 2017-2021" report to their offering. The global neutropenia treatment market to grow at a CAGR of 4.45% ...

BRUIN CLL-314 is the first-ever head-to-head Phase 3 study versus a covalent BTK inhibitor to include treatment-naïve patients INDIANAPOLIS, July 29, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: ...

Main Outcomes of the FRESH START Trial: A Sequentially Tailored, Diet and Exercise Mailed Print Intervention Among Breast and Prostate Cancer Survivors A total of 190 patients (49 smokers, 141 ...